Journal Finds Aussie Breast-Cancer Study Not Influenced By Drug Firm
This article was originally published in PharmAsia News
Executive Summary
Australian drug researcher John Eden has been exonerated of suggestions he may have had a drug maker ghost writer for his study linking progestin with reduced breast-cancer risk
Australian drug researcher John Eden has been exonerated of suggestions he may have had a drug maker ghost writer for his study linking progestin with reduced breast-cancer risk. John Eden's published research was questioned after U.S.-based Wyeth used the study in a promotion campaign for its hormone-replacement drugs. Eden said he had been duped into being part of the Wyeth's commercial agenda and now regrets his association with the company. His studies concluded high doses of progestin reduce the risk of a recurrence of the disease. (Click here for more) "Study Finds Reduced Cancer Risk" - Albany Weekender (Australia) (11/29/10) |